Patients with Rare Diseases Should Like the New FDA
The Study of the Week looks at Capricor Therapeutics drug for Duchenne Muscular Dystrophy. It's published in the Lancet so you can see FDA's reasoning....
Comment
Show comments
Hide Comments
